Payers may already be cooking up ways to reduce the $14,600 yearly price of Sanofi and Regeneron's new PCSK9 drug, Praluent. But to some patients, the drug is a bargain.
After winning approval for their PCSK9 drug Praluent last week, longtime partners Sanofi and Regeneron are back at it with a new collaboration. The French pharma giant will pay at least $1.8 billion in a new immuno-oncology deal that includes an early-stage checkpoint inhibitor.
A few months after conceding that its own in-house attempt to develop new cancer drugs had flopped, French pharma giant Sanofi will now let its close development partner Regeneron lead the way on a blockbuster collaboration on immuno-oncology--which includes an early-stage checkpoint inhibitor.
It's no surprise that Sanofi and Regeneron won FDA approval for Praluent, the PCSK9 cholesterol-fighter. But the drug's list price is another matter. At $14,600, it's almost 50% more than many analysts had estimated.
Sanofi and Regeneron won an expected FDA approval for the first of a new class of cholesterol drugs expected to alter the landscape in cardiology, but regulators stopped short of giving the treatment the wide label its makers wanted.
Sanofi and Regeneron may be on pace to win the first U.S. approval for a new type of cholesterol treatment, but the pair trails rival Amgen in Europe in a race to make good on blockbuster sales predictions.
Amgen may be running a beat or two behind Regeneron and Sanofi in search of the first FDA approval for a PCSK9 drug, but the Big Biotech scooped up the very first approval in Europe today for Repatha (evolocumab), giving the company boasting rights as first mover in what is widely seen as a new blockbuster market in the making.
The year's 10 highest-paid development executives pulled in $124.4 million in total compensation, a roughly 35% jump over 2013's top earners. And while each entrant benefited from meeting individual company goals, the whole group benefited from biopharma's macroeconomic moment in the sun, as the value of stock awards skyrocketed alongside the industry index.
You can't accuse Sanofi and Regeneron of slacking. Partners on the forthcoming cholesterol fighter, Praluent, the drugmakers have been laying an awareness foundation for months. A cholesterol-testing campaign, a patient-awareness poll, advocacy partnerships--and now, a documentary.
Eye blockbuster Eylea has been churning out serious revenue growth for Regeneron since it hit the market, and now the company is inching closer to approval for its much-watched PCSK9 therapy. But what comes after that for the New York biotech? Analysts disagree.